Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cridanimod - Pharmsynthez/Xenetic Biosciences

Next Previous
Drug Profile

Cridanimod - Pharmsynthez/Xenetic Biosciences

Alternative Names: Sodium cridanimod; Virexxa; XBIO-101

Latest Information Update: 07 Sep 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmsynthez
  • Developer AS Kevelt; Pharmsynthez; Xenetic Biosciences
  • Class Acetic acids; Acridines; Antineoplastics; Small molecules
  • Mechanism of Action Immunomodulators; Interferon stimulants; Progesterone receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Endometrial cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Endometrial cancer; Triple negative breast cancer

Most Recent Events

  • 07 Sep 2022 Discontinued - Phase-II for Endometrial cancer (Combination therapy, Recurrent, Second-line therapy or greater) in Belarus, Ukraine, Slovakia, Czech Republic, USA (IM)
  • 07 Sep 2022 Discontinued - Phase-II for Endometrial cancer (Late-stage disease, Second-line therapy or greater) in Russia (IM)
  • 07 Sep 2022 Discontinued - Preclinical for Triple-negative-breast cancer in USA (unspecified route)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top